Related Experiment Video
Updated: May 21, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a
Guillaume Bobrie1, Michael Frank, Michel Azizi
1Assistance Publique, Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France. guillaume.bobrie@egp.aphp.fr
Journal of Hypertension
|June 26, 2012
Summary
Sequential nephron blockade significantly lowered resistant hypertension blood pressure more effectively than sequential renin-angiotensin system blockade. This well-tolerated treatment offers a promising approach for managing difficult-to-treat hypertension.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Resistant hypertension affects a significant patient population, often requiring complex treatment strategies.
- Current treatment guidelines recommend multi-drug regimens, but achieving blood pressure control remains challenging.
Purpose of the Study:
- To compare the efficacy of sequential nephron blockade versus sequential renin-angiotensin system blockade in patients with resistant hypertension.
- To evaluate the blood pressure-lowering effects and tolerability of two distinct drug regimens.
Main Methods:
- A prospective, randomized, open-blinded endpoint study involving 167 patients with uncontrolled resistant hypertension.
- Patients were randomized to either sequential nephron blockade or sequential renin-angiotensin system blockade, with stepwise medication adjustments over 12 weeks.
- The primary endpoint was the change in systolic daytime ambulatory blood pressure at week 12.
Main Results:
- Sequential nephron blockade resulted in a significantly greater reduction in systolic and diastolic blood pressure compared to sequential renin-angiotensin system blockade (10/4 mmHg difference, P < 0.001).
- The blood pressure goal (<135/85 mmHg) was achieved in 58% of patients on sequential nephron blockade versus 20% on sequential renin-angiotensin system blockade (P < 0.0001).
- Both regimens were generally well-tolerated, with low rates of drug-related adverse event discontinuation.
Conclusions:
- Sequential nephron blockade is a highly effective and well-tolerated strategy for managing resistant hypertension.
- This approach, involving progressive sodium depletion, demonstrates superior efficacy compared to sequential renin-angiotensin system blockade.
- The findings support sequential nephron blockade as a preferred treatment option for patients with resistant hypertension.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...